Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04834089
Other study ID # SAS-01-IB
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date May 2021
Est. completion date May 2022

Study information

Verified date April 2021
Source Butantan Institute
Contact Ricardo Palacios, MD, PhD
Phone +551137232121
Email ricardo.palacios@butantan.gov.br
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase I/II Randomized Clinical Trial to evaluate the safety, pharmacokinetic and efficacy of Anti-SARS-CoV-2 hyperimmune serum. The study will include patients at early stage of COVID-19 with increased risk for severe disease due to underlying medical conditions to determine the utility of an equine heterologous serum anti-SARS-CoV-2 to avoid progression to a severe COVID-19


Description:

Phase I/II Clinical Trial, randomized, multicentric, on three stages (A, B and C) to evaluate the safety, pharmacokinetic and efficacy of Anti-SARS-CoV-2 serum and dose escalation. The study will be in three stages: Stage A: 30 kidney transplanted participants (very high risk), where 15 will received 1 vial (5 mL) and 15 will received 2 vials (10 mL) of serum; Stage B: 30 immunocompetent participants with at least 2 risk factors for severe disease (high risk) who will receive the dose selected by stage A; Stage C: 558 participants, of very high risk and high risk, compared with placebo in allocation 2:1 (endpoint-driven design) Allocation type Open study without allocation of randomization on Stages A and B Randomized allocation with placebo comparator in Stage C. Recruitment Status: On planning Date of 1st recruitment Expected: April 2021 Target sample siz 618 (30/30/538) participants .


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 618
Est. completion date May 2022
Est. primary completion date May 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adults 18 years of age or older; 2. Diagnosis of SARS-CoV-2 infection confirmed by RT-PCR or antigen test no more than 5 days ago; 3. Onset of clinical signs and symptoms of COVID-19 no more than 5 days manifested as: 1. Presenting sudden onset of anosmia and/or ageusia without any other reasonable explanation and/or; 2. Thoracic image by radiography, tomography or ultrasonography compatible with acute clinical symptoms findings of COVID-19 and/or; 3. Acute onset of cough accompanied by fever and/or 4. Acute onset of three or more of the following symptoms: fever, cough, fatigue or general weakness, headache, myalgia, sore throat, runny nose, dyspnea, anorexia or nausea or vomit, diarrhea and mental status change. 4. Oxygen saturation by pulse oximetry =92% 5. Agree to periodic contacts by phone, electronic means and home visits; 6. Demonstrate intention to participate in the study, documented by Informed Consent Form signature on the part of the participant. For the very high risk group: 7. Being on continuous drug immunosuppressant more than two weeks due to a basic medical condition (e.g. transplant or cancer); For the high risk group: 8. To present at least two risk factors for developing serious COVID-19 (Over 60 years of age; diabetes mellitus; chronic obstructive pulmonary disease; kidney disease; cardiovascular diseases and body mass index = 35). Exclusion Criteria: 1. Presenting COVID-9 in need of oxygen therapy on the moment of study inclusion, in other words, score 5 or higher in WHO COVID-19 progression scale; 2. Behavioral, cognitive or psychiatric disease that, in principal investigator opinion or his/her medical representative, affect the participant capacity in understanding and collaborating with study protocol requirements; 3. Any use considered alcohol or drugs abuse in the last 12 months prior to study inclusion that caused medical, professional or family problems, as indicated by clinical history; 4. Severe allergic reaction history or anaphylaxis to heterologous serum or product components of the study; 5. To have received heterologous serum or convalescent plasma in the last three months before of study inclusion, or planned administration of hemoderivatives or immunoglobulin on the next 28 days of study inclusion; 6. The participant is a team member who is conducting the study or is in a dependent relationship with one of the study team members. Dependency relationships include close relatives (in other words, sons, partner/spouse, brothers, parents), as well as Researcher staff or staff from the location conducting the study; 7. Any other condition that, in the principal investigator opinion or his/her medical representative, could threaten the safety or rights of a potential participant or which prevents him from fulfilling with this protocol. For female: 8. Pregnancy (confirmed by positive ß-hCG test), breastfeeding and/or expressing an intention to have sexual practices with reproductive potential without using a contraceptive method within four weeks of the product administration; For stages A and B: 9. Previous immunization with vaccine against COVID-19

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
AntiSARS-CoV-2 Serum
Stage A: 30 kidney transplanted participants (very high risk), where 15 will received 1 vial (5 mL) and 15 will received 2 vials (10 mL) of serum; Stage B: 30 immunocompetent participants with at least 2 risk factors for severe disease (high risk) who will receive the dose selected by stage A; Stage C: 558 participants, of very high risk and high risk, compared with placebo in allocation 2:1.
Other:
Placebo
Saline solution Administration Route: Intravenous

Locations

Country Name City State
Brazil Hospital do Rim Sao Paulo SP
Brazil Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo São Paulo

Sponsors (1)

Lead Sponsor Collaborator
Butantan Institute

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Other Frequency and magnitude of equine antibodies titers Frequency and magnitude of equine antibodies titers 14 and 28 days after administration of anti-SARS-CoV-2 serum 28 days after product administration
Other Frequency and magnitude of neutralizing antibodies titers Against SARS-CoV-2 Frequency and magnitude of neutralizing antibodies titers Against SARS-CoV-2 after administration of anti-SARS-CoV-2 serum 28 days after product administration
Other Proportion of medical assistance Proportion of medical assistance related to COVID-19 (score = 3 of WHO) 14 days after product administration
Other Proportion of emergency service visit Proportion of emergency service visit related to COVID-19 14 days after product administration
Other Proportion of hospitalization Proportion of hospitalization related to COVID-19 (defined as =24 hours of hospital care) (score = 4 of WHO) 14 days after product administration
Other Proportion of patients with change in COVID-19 disease progression Proportion of patients with change in COVID-19 disease progression profile after administration of anti-SARS-CoV-2 serum according to underlying medical conditions. 28 days after product administration
Primary Frequency of local and systemic adverse events Frequency of local and systemic adverse events, solicited and unsolicited, during the infusion and within 12 hours after administration of the heterologous serum 12 hours after product administration
Primary Anti-SARS-CoV-2 serum average life Anti-SARS-CoV-2 serum average life measured by equine antibodies levels 28 days after product administration
Primary Proportion of patients with change in COVID-19 disease progression profile after administration of anti-SARS-CoV-2 serum Proportion of patients with change in COVID-19 disease progression profile after administration of anti-SARS-CoV-2 serum, based on the WHO clinical progression scale (not progression to severe disease requiring mechanical ventilation or death - Score 7 or larger) 14 days after product administration
Secondary Frequency of local and systemic adverse events Frequency of local and systemic adverse events, solicited and unsolicited, up to 28 days of serum heterologous administration 28 days after product administration
Secondary Frequency of severe adverse events Frequency of severe adverse events and of the special interest up to 28 days after administration of serum heterologous 28 days after product administration
Secondary Clinical response Clinical response according serum anti-SARS-CoV-2 dosage 14 days after product administration
Secondary Symptoms duration Symptoms duration associated to COVID-19 28 days after product administration
Secondary Hospitalization time in Intensive Care Unit Hospitalization time in Intensive Care Unit related to COVID-19 28 days after product administration
Secondary Deaths Frequency of deaths by COVID-19 28 days after product administration
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases